303.81 USD
-0.91 (-0.3%)
303.81 USD
0 (0%)
Taking everything into account, ONC scores 5 out of 10 in our fundamental rating. ONC was compared to 530 industry peers in the Biotechnology industry. The financial health of ONC is average, but there are quite some concerns on its profitability. ONC is growing strongly while it also seems undervalued. This is an interesting combination
1. Profitability
1.1 Basic Checks
ONC had positive earnings in the past year.
ONC had a positive operating cash flow in the past year.
In the past 5 years ONC always reported negative net income.
ONC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ONC's Return On Assets of -3.68% is amongst the best of the industry. ONC outperforms 86.42% of its industry peers.
ONC has a better Return On Equity (-6.15%) than 88.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.68% | ||
| ROE | -6.15% | ||
| ROIC | N/A |
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ONC (85.37%) is better than 87.92% of its industry peers.
ONC's Gross Margin has been stable in the last couple of years.
ONC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
2. Health
2.1 Basic Checks
ONC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ONC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ONC has been increased compared to 5 years ago.
ONC has a worse debt/assets ratio than last year.
2.2 Solvency
ONC has an Altman-Z score of 6.99. This indicates that ONC is financially healthy and has little risk of bankruptcy at the moment.
ONC has a better Altman-Z score (6.99) than 77.36% of its industry peers.
ONC has a debt to FCF ratio of 5.47. This is a neutral value as ONC would need 5.47 years to pay back of all of its debts.
ONC has a better Debt to FCF ratio (5.47) than 92.08% of its industry peers.
ONC has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
ONC's Debt to Equity ratio of 0.26 is on the low side compared to the rest of the industry. ONC is outperformed by 68.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.47 | ||
| Altman-Z | 6.99 |
ROIC/WACCN/A
WACC4.78%
2.3 Liquidity
ONC has a Current Ratio of 1.94. This is a normal value and indicates that ONC is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.94, ONC is doing worse than 76.98% of the companies in the same industry.
A Quick Ratio of 1.71 indicates that ONC should not have too much problems paying its short term obligations.
The Quick ratio of ONC (1.71) is worse than 79.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.71 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 215.42% over the past year.
The Revenue has grown by 50.62% in the past year. This is a very strong growth!
The Revenue has been growing by 55.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)215.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%188.84%
Revenue 1Y (TTM)50.62%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.84%
3.2 Future
Based on estimates for the next years, ONC will show a very strong growth in Earnings Per Share. The EPS will grow by 97.88% on average per year.
ONC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.65% yearly.
EPS Next Y139.04%
EPS Next 2Y70.78%
EPS Next 3Y50.9%
EPS Next 5Y97.88%
Revenue Next Year41.33%
Revenue Next 2Y31.33%
Revenue Next 3Y25.89%
Revenue Next 5Y19.65%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 4.70, the valuation of ONC can be described as very cheap.
Based on the Price/Earnings ratio, ONC is valued cheaply inside the industry as 99.25% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ONC to the average of the S&P500 Index (26.77), we can say ONC is valued rather cheaply.
A Price/Forward Earnings ratio of 45.93 indicates a quite expensive valuation of ONC.
ONC's Price/Forward Earnings ratio is rather cheap when compared to the industry. ONC is cheaper than 90.94% of the companies in the same industry.
ONC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.7 | ||
| Fwd PE | 45.93 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, ONC is valued cheaper than 90.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 174.91 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ONC's earnings are expected to grow with 50.90% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y70.78%
EPS Next 3Y50.9%
5. Dividend
5.1 Amount
No dividends for ONC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
303.81
-0.91 (-0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners33.86%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change-12.71%
Market Cap33.62B
Revenue(TTM)35.67B
Net Income(TTM)-1.65B
Analysts82.5
Price Target335.18 (10.33%)
Short Float %16.31%
Short Ratio4.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.55
Dividend Growth(5Y)N/A
DP-30.61%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2148.49%
Min EPS beat(2)1187.13%
Max EPS beat(2)3109.85%
EPS beat(4)3
Avg EPS beat(4)1518.68%
Min EPS beat(4)-22.81%
Max EPS beat(4)3109.85%
EPS beat(8)4
Avg EPS beat(8)536.4%
EPS beat(12)5
Avg EPS beat(12)344.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.52%
Min Revenue beat(2)-1.25%
Max Revenue beat(2)6.29%
Revenue beat(4)3
Avg Revenue beat(4)2.7%
Min Revenue beat(4)-1.25%
Max Revenue beat(4)6.29%
Revenue beat(8)7
Avg Revenue beat(8)13.13%
Revenue beat(12)11
Avg Revenue beat(12)13.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.99%
PT rev (3m)-2.72%
EPS NQ rev (1m)-1.13%
EPS NQ rev (3m)6.22%
EPS NY rev (1m)36.62%
EPS NY rev (3m)93.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)0.76%
Revenue NY rev (3m)-0.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.7 | ||
| Fwd PE | 45.93 | ||
| P/S | 7.18 | ||
| P/FCF | 174.91 | ||
| P/OCF | 67.66 | ||
| P/B | 8.75 | ||
| P/tB | 9.18 | ||
| EV/EBITDA | N/A |
EPS(TTM)64.63
EY21.27%
EPS(NY)6.61
Fwd EY2.18%
FCF(TTM)1.74
FCFY0.57%
OCF(TTM)4.49
OCFY1.48%
SpS42.3
BVpS34.71
TBVpS33.1
PEG (NY)0.03
PEG (5Y)N/A
Graham Number224.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.68% | ||
| ROE | -6.15% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.37% | ||
| FCFM | 4.11% |
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
F-Score6
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.51% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.71 | ||
| Altman-Z | 6.99 |
F-Score6
WACC4.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)20.18%
Cap/Sales(5y)27.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)215.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%188.84%
EPS Next Y139.04%
EPS Next 2Y70.78%
EPS Next 3Y50.9%
EPS Next 5Y97.88%
Revenue 1Y (TTM)50.62%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.84%
Revenue Next Year41.33%
Revenue Next 2Y31.33%
Revenue Next 3Y25.89%
Revenue Next 5Y19.65%
EBIT growth 1Y89.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year206.46%
EBIT Next 3Y69.73%
EBIT Next 5Y61%
FCF growth 1Y110.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y136.32%
OCF growth 3YN/A
OCF growth 5YN/A
BEONE MEDICINES LTD-ADR / ONC FAQ
What is the ChartMill fundamental rating of BEONE MEDICINES LTD-ADR (ONC) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ONC.
Can you provide the valuation status for BEONE MEDICINES LTD-ADR?
ChartMill assigns a valuation rating of 7 / 10 to BEONE MEDICINES LTD-ADR (ONC). This can be considered as Undervalued.
How profitable is BEONE MEDICINES LTD-ADR (ONC) stock?
BEONE MEDICINES LTD-ADR (ONC) has a profitability rating of 3 / 10.
Can you provide the financial health for ONC stock?
The financial health rating of BEONE MEDICINES LTD-ADR (ONC) is 4 / 10.
Can you provide the dividend sustainability for ONC stock?
The dividend rating of BEONE MEDICINES LTD-ADR (ONC) is 0 / 10 and the dividend payout ratio is -30.61%.